KEEP UP WITH THE LATEST IN INDUSTRY NEWS!
From news about new medicines, pharmacy business insights, and the pharmaceutical industry in general—this is your source!
Drug Topics articles
- <![CDATA[Pharmacist-Led Transitions of Care Could Be Crucial in HIV Treatment]]> November 12, 2026
- <![CDATA[Wicked Good Cardiometabolic Chat: Ketone Monitoring in Pharmacy Practice]]> November 11, 2026
- <![CDATA[The Outcome-Based Program That Could Reshape Pharmacists’ Roles]]> November 11, 2026
- <![CDATA[FDA Approves Asundexian, First FXIa Inhibitor for Stroke Prevention]]> November 11, 2026
- <![CDATA[High Triglycerides Independently Linked with Severe COVID-19 Death]]> November 10, 2026
- <![CDATA[Q&A: Antiretroviral Formulary Protocol Cuts Costs, Eases Workflow]]> November 10, 2026
- <![CDATA[FDA Adds NAION Eye Risk Warning to All GLP-1 Labels]]> November 10, 2026
- <![CDATA[FDA Grants Tentative Approval for First Generic Lenacapavir]]> November 9, 2026
- <![CDATA[ACCESS to Pharmacy Care Model Lets Pharmacists Bill for Chronic Care]]> November 9, 2026
- <![CDATA[US Lost Over 3000 Pharmacies From 2022 to 2024, Mostly Chains]]> November 7, 2026
Pharmacy Times articles
- <![CDATA[Closing the Data and Education Gaps in Cardiac Medication Management]]> November 12, 2026
- <![CDATA[Adjusting Cardiac Medications in Pregnancy and Lactation Varies By Disease State, Panelists Say]]> November 12, 2026
- <![CDATA[Pharmacists Weigh In on Specialty Medication Barriers and Shifting Industry Dynamics]]> November 12, 2026
- <![CDATA[Program Directors Make the Case for PGY2 Training to Build the Neurology Pharmacy Pipeline]]> November 12, 2026
- <![CDATA[Where NSCLC Treatment Stalls: Staffing, Testing, and Infusion Chair Access]]> November 12, 2026
- <![CDATA[Changing NSCLC Immunotherapy Practice: Data, Formulations, Payers, and Operations]]> November 12, 2026
- <![CDATA[Garlic: Untangling the Complexities of a “Natural” Remedy]]> November 11, 2026
- <![CDATA[The Most Accessible Healthcare Professional—But Accessible to Whom?]]> November 11, 2026
- <![CDATA[Cancer Pain Care Requires More Than an Opioid Prescription]]> November 11, 2026
- <![CDATA[How Lab-Based Risk Flags Help Overcome Clinical Inertia in CKD ]]> November 11, 2026
Helping You Navigate the Returns Process!
Pedigree Statement
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with it’s clients…
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with its clients. This is to ensure that the reverse distribution portion of the supply chain that we service keeps its functionality and integrity for our customers and the public.
Several pedigree and distribution level issues have been raised in the industry. Discounted, indigent-pricing, short dated, bulk purchase, secondary distribution, or DSCSA non-compliant sales could affect the credit available for a product based on a manufacturers determination. We ask that you do not return these products for credit as they are not eligible in most cases. Flash Returns LLC may choose to dispose of these on the pharmacies behalf at no charge if the cost is low relative to the return. Most customers purchasing products from reputable wholesalers will not encounter these issues, however all pharmacies are asked to acknowledge our policy on pedigree and legitimacy of product here and by signing the PSA before a return is initiated.
Some manufacturers may require proof the price paid for a product and what wholesaler distributed the product. Issues causing triggering this could be: bulk or large quantities of single items or lots, or products purchased speculatively. In some cases we may request invoices from the customer to ensure Flash Returns or manufacturer policy is being met. If none are available or if the information isn’t accepted by the manufacturer it could cause the return to be non-returnable.
Flash Returns, LLC cannot guarantee or be liable for the value or credit for products that were purchased outside of manufacturer accepted distribution channels. This could include products: purchased from a wholesaler that is not an approved vendor, products not purchased directly from a particular manufacturer, purchased on a speculative basis, diverted or counterfeit products, foreign products, and any product purchased on a non-returnable basis, including short-dated product purchased at discounted pricing.
At any time, Flash Returns, LLC or a manufacturer may require invoices or pedigree information demonstrating proof of purchase. If product has been shipped by Flash Returns, LLC or the Customer to a manufacturer or their agent, Flash Returns, LLC cannot guarantee or facilitate the return of product to the Customer. Manufacturers reverse the right to destroy product they deem not credit worthy or suspect. Manufacturers agreeing to return product to customers will do so at the customers expense. Flash Returns, LLC shall not be responsible for reimbursing a Customer for such product.
If Customer is unable to have product returned within 21 days, product is subject to be destroyed without any payment or credit issued to Customer. In any dispute, failure by Customer to provide invoices for a product or pedigree if requested shall release Flash Returns, LLC from any and all liability of products involved in dispute including the full value of the product. More information on drug pedigrees is available on the FDA website at:
Pedigree Statement
P: 833.553.5274
E: SignUp@FlashReturns.com
